1. Home
  2. NVNI vs RFL Comparison

NVNI vs RFL Comparison

Compare NVNI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

HOLD

Current Price

$1.28

Market Cap

12.9M

Sector

N/A

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.34

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVNI
RFL
Founded
2019
2017
Country
Brazil
United States
Employees
618
N/A
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
61.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
NVNI
RFL
Price
$1.28
$1.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
85.1K
92.9K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.28
EPS
N/A
N/A
Revenue
N/A
$917,000.00
Revenue This Year
$6.67
N/A
Revenue Next Year
$26.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$0.14
$1.12
52 Week High
$4.94
$3.19

Technical Indicators

Market Signals
Indicator
NVNI
RFL
Relative Strength Index (RSI) 36.29 48.08
Support Level $1.10 $1.15
Resistance Level $1.64 $1.38
Average True Range (ATR) 0.13 0.12
MACD 0.04 -0.00
Stochastic Oscillator 39.54 30.00

Price Performance

Historical Comparison
NVNI
RFL

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: